Directorate Change

GlaxoSmithKline PLC
26 May 2004



Issued - 26th May 2004, London


                              GLAXOSMITHKLINE PLC 
 
                            ANNOUNCES BOARD CHANGES



GlaxoSmithKline plc (GSK) announces that Sir Christopher Gent and Sir Deryck
Maughan are to join the Board of the Company as Non-Executive Directors with
effect from 1st June 2004. It is also announced that Sir Christopher Hogg will
retire from the Board on 31st December 2004.



Sir Christopher Gent has been appointed Deputy Chairman and will succeed Sir
Christopher Hogg as Non-Executive Chairman with effect from 1st January 2005.



Commenting on the appointments, Sir Christopher Hogg, Chairman of GSK, said "I
am delighted that Chris and Deryck are joining the Board.



Sir Christopher brings with him many years of experience and a track record of
delivering outstanding performance in a highly competitive global industry which
will be invaluable to GSK.



Sir Deryck brings with him a wealth of international corporate and investment
banking experience, which will be of great value to the Board.



My colleagues and I very much look forward to welcoming Chris and Deryck to the
Board."



Biographical details of Sir Christopher Gent and Sir Deryck Maughan are given
below.









S M Bicknell

Company Secretary



26th May 2004











BIOGRAPHICAL DETAILS 


Sir Christopher Gent



Age 56.  Sir Christopher is the former Chief Executive Officer of Vodafone Group
Plc. Prior to his retirement from Vodafone in July 2003, he had been a member of
its Board since August 1985 and its Chief Executive Officer since January 1997.
He was also Chairman of the Supervisory Board of Mannesmann AG; a non-executive
director of China Mobile (Hong Kong) Limited; and on the Board of Verizon
Wireless.  Sir Christopher joined Vodafone as Managing Director of Vodafone
Limited in January 1985 when the mobile phone service was first launched, and
held that position until December 1996.



Prior to joining Vodafone, Sir Christopher was Director of Network Services at
ICL. In this role, he was Managing Director of Baric, a computer services
company owned jointly by Barclays and ICL, and was responsible for ICL's
computer bureau services worldwide.



Sir Christopher served as the National Chairman of the Young Conservatives from
1977 to 1979, and was Vice President of the Computer Services Association
Council at the time he left ICL.



He is a non-executive director of Lehman Brothers Holdings Inc; a director of
the International Advisory Board of Hakluyt & Co; and is a Senior Adviser at
Bain & Co.



Sir Deryck Maughan



Age 56. Sir Deryck is Chairman and Chief Executive Officer of Citigroup
International and Vice Chairman of Citigroup Inc. He is responsible for
Citigroup's business in Europe, Japan, Asia, Africa and Latin America. Prior to
this he led group Strategy and Acquisitions.



Prior to the creation of Citigroup in 1998, Sir Deryck was a Director of
Travelers Group and Chairman and Co-Chief Executive Officer of Salomon Smith
Barney. From 1992 to 1997 he was Chairman and Chief Executive Officer of Salomon
Brothers, a firm he joined in 1983. From 1969 to 1979 he served as a member of
H.M. Treasury in London and from 1979 to 1983 he worked at Goldman Sachs.



Sir Deryck serves on the Boards of Directors of Carnegie Hall, Lincoln Center
and NYU Medical Center. He is Chairman of the Japan Society and the US-Japan
Business Council. He is also a Board member of British American Business Inc.,
the American Academy in Berlin and the Trilateral Commission. He served as Vice
Chairman of the New York Stock Exchange from 1996 to 2000.



Notes



1.         The appointment of Sir Christopher Gent as Deputy Chairman and Sir
Deryck Maughan as a Non-Executive Director have been made by the Board on the
recommendation of the Nominations Committee which is chaired by Sir Christopher
Hogg and comprises two other independent Non-Executive Directors.



2.         Sir Christopher Gent will receive total fees of £300,000 per annum in
his role as Deputy Chairman comprising £240,000 in cash together with
GlaxoSmithKline plc Ordinary Shares to the value of £60,000.   On his
appointment as Chairman, from 1st January 2005, he will receive total fees of
£500,000 per annum comprising £400,000 in cash together with GlaxoSmithKline plc
Ordinary Shares to the value of £100,000.



3.         Sir Deryck Maughan will receive fees of £45,000 per annum and 1,000
GlaxoSmithKline plc Ordinary Shares per annum.



4.         Neither Sir Christopher Gent nor Sir Deryck Maughan have service
contracts.  They both have letters of appointment which may be viewed by
contacting the Company Secretary at the Company's registered office.



5.         Sir Christopher Gent will be based at GSK's registered office at 980
Great West Road, Brentford, Middlesex, TW8 9GS.



6.         The Board has determined that Sir Christopher Gent and Sir Deryck
Maughan are both independent Non-Executive Directors in accordance with the new
Combined Code on Corporate Governance.



7.         With effect from 1st June 2004 the composition of the Board of
GlaxoSmithKline plc will be as follows:



Sir Christopher Hogg             Non-Executive Chairman

Sir Christopher Gent             Non-Executive Deputy Chairman

Sir Ian Prosser                  Senior Independent Non-Executive Director

Dr J-P Garnier                   Chief Executive Officer

Mr J D Coombe                    Chief Financial Officer

Dr Tachi Yamada                  Executive Director, Chairman, Research & Development

Mr H Lawrence Culp               Independent Non-Executive Director

Mr C Davis                       Independent Non-Executive Director

Sir Peter Job                    Independent Non-Executive Director

Sir Deryck Maughan               Independent Non-Executive Director

Dr Ronaldo Schmitz               Independent Non-Executive Director

Dr Lucy Shapiro                  Non-Executive Director

Sir Robert Wilson                Independent Non-Executive Director





Enquiries:

UK Media enquiries:                                    Martin Sutton           [phone]
                                                       David Mawdsley          [phone]
                                                       Chris Hunter-Ward       [phone]

US Media enquiries:                                    Nancy Pekarek           [phone]
                                                       Mary Anne Rhyne         [phone]
                                                       Patricia Seif           (215)  751 7709

European Analyst/Investor enquiries:                   Duncan Learmouth        [phone]
                                                       Anita Kidgell           [phone]
                                                       Philip Thomson          [phone]

US Analyst/ Investor enquiries:                        Frank Murdolo           [phone]
                                                       Tom Curry               [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange